On this page
Updated and source-checked 6 October 2026. The US Food and Drug Administration has expanded its public warning about unapproved GLP-1-related products used for weight loss, including products promoted as semaglutide, tirzepatide, retatrutide, survodutide and mazdutide.
The warning matters beyond the United States because it describes a global information problem: online listings can borrow the name of a studied molecule without establishing that the supplied material has the stated identity, strength, quality or regulatory status.
The warning in one table
| Product or claim | FDA concern | What readers should not assume |
|---|---|---|
| Unapproved semaglutide or tirzepatide | No FDA premarket review for safety, effectiveness or quality | That “same ingredient” or “generic” language makes it equivalent to an approved medicine |
| Retatrutide or cagrilintide sold outside trials | Not components of FDA-approved drugs; the FDA says they cannot lawfully be used in US compounding | That a clinical-trial molecule name creates a lawful consumer product |
| “Research use only” product marketed for people | Labelling can conflict with the product’s actual promotion and intended use | That a disclaimer proves identity, quality, legality or safety |
| Fraudulent compounded label | The named pharmacy may not exist or may not have made the product | That a professional-looking label establishes provenance |
| Counterfeit product | May contain the wrong amount, wrong ingredient, no active ingredient or harmful ingredients | That packaging or a familiar brand/molecule name establishes authenticity |
A specific product was assessed for a defined indication and presentation.
Prepared under a compounding framework; not automatically equivalent to an approved product.
A marketing label. It does not establish identity, quality, approval or lawful human use.
Falsely represented product or packaging; contents may differ from the label.
Decision rule: verify the exact product, sponsor, regulator record and supply pathway. A molecule name alone cannot answer those questions.
What the FDA says
The agency distinguishes approved medicines from compounded, counterfeit and illegally marketed versions. Unapproved versions do not undergo FDA review for safety, effectiveness or quality before marketing. The FDA also says retatrutide and cagrilintide are not components of FDA-approved drugs and cannot be used in US compounding under federal law.
Its enforcement concerns include telehealth marketing, sales of active pharmaceutical ingredients, fraudulent pharmacy labels, products presented as “research use only” while being sold directly for human use, and online products that may contain the wrong ingredient, too much, too little or no active ingredient.
Approved, compounded, counterfeit and “research use only” are different categories
| Category | What it means | Evidence or oversight limit |
|---|---|---|
| FDA-approved medicine | A specific product reviewed for defined indications, manufacturing and labelling | Approval does not transfer to a different seller, formulation or falsely labelled copy |
| Compounded drug | A patient-specific or outsourcing-facility preparation made under applicable US compounding law | It is not FDA-approved and circumstances of lawful compounding are limited |
| Counterfeit | A product falsely represented as authentic | Identity and contents may be wrong or unknown |
| “Research use only” listing | A marketing label or disclaimer | It does not establish that promotion for human use is lawful or that quality has been verified |
| Clinical-trial material | Investigational material controlled under a study protocol | It is not interchangeable with an online vial using the same molecule name |
Semaglutide sodium and acetate: why the ingredient name matters
A shared semaglutide name does not establish an equivalent active ingredient. The FDA identifies semaglutide sodium and semaglutide acetate as different active ingredients from those used in approved drugs. It says it lacks information on whether these salts have the same chemical and pharmacologic properties, and is unaware of a lawful basis for their use in US compounding.
| Claim | What must be distinguished |
|---|---|
| Ingredient identity | The exact substance, including whether a salt form is named. |
| Analytical quality | An identity or purity result does not establish clinical equivalence. |
| Regulatory status | Assessment of an approved product does not transfer to a different preparation. |
Targeted source check: 27 October 2026. FDA guidance, salt-forms section. This describes the US position; Australian status requires separate TGA assessment.
Reported safety signals are not a denominator
As of 31 May 2026, the FDA reported receiving 990 adverse-event reports associated with compounded semaglutide and more than 730 associated with compounded tirzepatide. These figures are signals, not incidence rates: the total number of exposed people is not supplied, reporting is incomplete, and a report does not by itself prove causation.
The agency describes reported problems including dosing errors, use beyond approved labelling, inadequate refrigeration during shipping, multi-dose vial contamination risk and semaglutide salt forms that differ from the active ingredient used in approved products.
How to read the adverse-event numbers
The FDA totals are surveillance counts, not a calculation of risk. They do not provide the number of exposed patients, a verified causal fraction, consistent product provenance or a comparison group. Under-reporting is also plausible because many state-licensed pharmacies are not federally required to submit reports in the same way as outsourcing facilities.
| What the count can show | What the count cannot show by itself |
|---|---|
| A safety signal requiring investigation | The incidence rate among all users |
| The types of problems reported to the FDA | That the product caused every reported event |
| Why quality and labelling controls matter | Whether one seller or formulation accounts for the reports |
Why a familiar molecule name is not enough
A product name is a claim, not analytical proof. Identity requires a suitable analytical method and reference standard. Strength, purity, sterility, endotoxin, residual solvents and stability are separate questions. Even a complete certificate of analysis would not establish that an unapproved product is safe or effective for human use.
A six-part identity and quality check
- Identity: is the detected molecule the one claimed?
- Assay or strength: how much target substance is present?
- Impurities: what related and unrelated substances were detected?
- Sterility and endotoxin: were appropriate microbiological controls tested?
- Stability and shipping: did the product remain within specification through storage and transport?
- Traceability: can the physical item be connected to its manufacturer, batch and test record?
Our HPLC chromatogram guide and lab test versus TGA approval guide explain why one purity percentage cannot answer all six questions.
9 October 2026: FDA import controls for GLP-1 active ingredients
The FDA’s revised Import Alert 66-80 concerns GLP-1 bulk drug substances, also called active pharmaceutical ingredients (APIs). It recommends detention without physical examination (DWPE) for covered foreign-sourced material that appears adulterated, with specified firm/product exceptions on its Green List.
FDA reports evaluating 48 GLP-1 API sites and finding 21% noncompliant under the provisions it cites. The reasons include manufacturing-compliance evidence and failure to respond promptly to records requests. This is the evaluated group, not a measured failure rate for every GLP-1 manufacturer or medicine.
The 9 October revision adds orforglipron-related product codes and Green List entries. An API import-control entry does not authorise every finished product containing the named ingredient.
How to read the alert: DWPE is an import-enforcement mechanism. An import alert, product recall, finished-medicine approval and clinical-trial result answer different questions. A Green List entry is also limited to the firm/product scope evaluated by FDA.
The quality question remains broader than a single chromatogram: analytical testing, manufacturing controls and regulatory product assessment each have distinct roles. See our laboratory evidence and approval guide. Alert checked: 22 October 2026.
Australian context
The FDA notice is a US regulatory source and should not be treated as an Australian legal ruling. However, its quality distinctions align with the reasoning behind the Australian Therapeutic Goods Administration’s 14 September 2026 retatrutide alert. In that case, the TGA reported that a tested product marketed as retatrutide contained undeclared semaglutide and no retatrutide.
Read our TGA retatrutide alert analysis and Australian guide to ARTG inclusion and unapproved therapeutic goods.
Frequently asked questions
Are compounded GLP-1 products FDA-approved?
No. Compounded drugs are not FDA-approved. The FDA does not review them for safety, effectiveness and quality before marketing in the same way as an approved medicine.
Does “research use only” make a product safe or lawful for human use?
No. The phrase does not establish identity, manufacturing quality, legal supply, sterility, clinical effectiveness or safety.
Are retatrutide and cagrilintide approved GLP-1 medicines?
No. The FDA states that neither is a component of an FDA-approved drug and that they cannot be used in US compounding under federal law.
Do 990 semaglutide reports mean 990 proven injuries caused by compounding?
No. These are reports received by the FDA, not incidence rates or automatically proven causal cases. Exposure totals and complete denominators are unavailable.
Does an FDA warning decide Australian legal status?
No. FDA material governs the US context. Australian approval, advertising and supply questions must be checked against the TGA and ARTG.
Source
Primary source: FDA — Concerns with Unapproved GLP-1 Drugs Used for Weight Loss, reviewed 6 October 2026.
This article provides general scientific and regulatory information, not medical advice.
How to cite this article
FDA Warning on Unapproved GLP-1 Products and “Research Use Only” Marketing. Elite Peps Australia. Published 14 September 2026; updated 27 October 2026. https://elitepepsaustralia.com/fda-warning-unapproved-glp-1-research-use-only-products-2026/
Source checks: Consult the primary studies, trial records and regulator documents linked in this article for current evidence and status. Publication and update dates do not by themselves indicate an evidence review.